Skip to main content
. 2021 Mar 18;35(5):e23757. doi: 10.1002/jcla.23757

TABLE 4.

The performance discriminative ability between FPR, CA199, and the combined score in metastatic CMA patients.

Biomarkers Progression‐free survival
AUROC(95%CI) Sensitivity Specificity
FPR 0.703(0.499–0.906) 42.11% 100.00%
CA19‐9 0.824(0.683–0.966) 64.86% 100.00%
CA19‐9‐FPR score 0.892(0.788–0.996) 76.32% 100.00%

FPR: fibrinogen‐to‐pre‐albumin ratio ×1000; AUROC: area under time‐dependent receiver operating characteristic curve; CI: confidence interval.